Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07430332 · ClinicalTrials.gov registry record · Phase 2
GLP-1 RA for Stage 1 Type 1 Diabetes
A Phase 2 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Not yet
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT07430332 is a Phase 2 study that has not yet begun recruiting, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 15 participants.
The verdict
NCT07430332, a Phase 2 study, has not yet begun recruiting, sponsored by Children's Hospital Medical Center, Cincinnati.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.
Interventions
- DRUG Placebo
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2027-09-01 |
| Est. Completion | 2030-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07430332
The ClinicalTrials.gov registry entry for NCT07430332 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07430332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07430332 about?
NCT07430332 is a clinical study titled "GLP-1 RA for Stage 1 Type 1 Diabetes". This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and ...
What is the current status of trial NCT07430332?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2027-09-01. Estimated completion is 2030-01-01.
What interventions are being tested in trial NCT07430332?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT07430332?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.